TABLE 2. Health care encounters associated with SARS-CoV-2 infections in vaccinated and unvaccinated persons — Oregon and Washington, July 4–September 25, 2021*.
| Characteristic | Health care encounters, no. (%) |
|||||||
|---|---|---|---|---|---|---|---|---|
| Among vaccinated patients (n = 3,009) |
Among unvaccinated patients (n = 4,146) |
|||||||
| Hospitalization | ED visit | Outpatient visit† | Virtual visit§ | Hospitalization | ED visit | Outpatient visit† | Virtual visit§ | |
|
Overall
|
117 (3.9)
|
244 (8.1)
|
862 (28.7)
|
2,696 (89.6)
|
375 (9.0)
|
767 (18.5)
|
1,246 (30.1)
|
3,695 (89.1)
|
|
COVID-19 vaccine manufacturer
| ||||||||
| Janssen (Johnson & Johnson) |
21 (6.9) |
33 (10.9) |
88 (29.0) |
273 (90.1) |
NA |
NA |
NA |
NA |
| Pfizer-BioNTech |
81 (3.9) |
168 (8.1) |
570 (27.4) |
1,868 (89.7) |
NA |
NA |
NA |
NA |
| Moderna |
15 (2.4) |
43 (6.9) |
204 (32.7) |
555 (89.1) |
NA |
NA |
NA |
NA |
|
Race/Ethnicity¶
| ||||||||
| White, NH |
94 (4.4) |
180 (8.4) |
616 (28.6) |
1947 (90.3) |
269 (9.5) |
534 (18.9) |
851 (30.1) |
2,530 (89.6) |
| Hispanic |
10 (2.9) |
27 (7.7) |
110 (31.5) |
305 (87.4) |
30 (6.9) |
74 (16.9) |
142 (32.5) |
396 (90.6) |
| Non-White, NH |
11 (3.8) |
28 (9.6) |
85 (29.0) |
270 (92.2) |
54 (12.4) |
105 (24.1) |
164 (37.7) |
394 (90.6) |
| Unknown |
≤5 (—) |
9 (4.2) |
51 (24.1) |
174 (82.1) |
22 (4.9) |
54 (12.0) |
89 (19.8) |
375 (83.3) |
|
Sex
| ||||||||
| Female |
63 (3.7) |
138 (8.1) |
493 (28.8) |
1,553 (90.8) |
163 (7.9) |
383 (18.5) |
661 (31.9) |
1,884 (90.8) |
| Male |
54 (4.2) |
106 (8.2) |
369 (28.4) |
1,143 (88.0) |
212 (10.3) |
384 (18.6) |
585 (28.3) |
1,807 (87.4) |
|
Age group, yrs
| ||||||||
| 12–17 |
0 (—) |
0 (—) |
6 (12.5) |
41 (85.4) |
≤5 (—) |
15 (3.5) |
84 (19.8) |
365 (86.1) |
| 18–24 |
0 (—) |
8 (3.5) |
54 (23.7) |
195 (85.5) |
10 (1.6) |
46 (7.4) |
150 (24.1) |
532 (85.4) |
| 25–34 |
≤5 (—) |
10 (2.1) |
131 (27.4) |
413 (86.4) |
35 (3.9) |
104 (11.5) |
238 (26.4) |
802 (88.8) |
| 35–44 |
≤5 (—) |
24 (4.4) |
135 (25.0) |
481 (89.1) |
39 (5.2) |
124 (16.5) |
211 (28.0) |
677 (89.8) |
| 45–54 |
12 (2.1) |
33 (5.9) |
167 (29.8) |
495 (88.2) |
92 (14.2) |
169 (26.1) |
234 (36.2) |
578 (89.3) |
| 55–64 |
21 (4.4) |
40 (8.4) |
131 (27.6) |
433 (91.2) |
77 (16.0) |
144 (29.9) |
179 (37.2) |
444 (92.3) |
| 65–74 |
36 (8.6) |
67 (16.0) |
138 (32.9) |
390 (92.9) |
63 (30.3) |
93 (44.7) |
100 (48.1) |
199 (95.7) |
| ≥75 |
43 (16.6) |
62 (23.9) |
100 (38.6) |
248 (95.8) |
55 (51.9) |
72 (67.9) |
50 (47.2) |
98 (92.5) |
| Median age, yrs (range) | 71 (27–95) | 65.5 (19–101) | 51 (14–101) | 48.5 (12–101) | 56 (15–100) | 50 (12–100) | 42 (12–100) | 36 (12–100) |
Abbreviations: ED = emergency department; NA = not applicable; NH = non-Hispanic.
* Health care encounters were defined as hospitalizations, ED visits, outpatient visits, or virtual care visits identified in the period 3 days before through 14 days after the first positive SARS-CoV-2 molecular test date; numbers shown represent the number and percentage of persons with each type of encounter; persons might have received care in multiple encounter settings.
† In-person ambulatory clinic or urgent care visit.
§ Telephone or video visit, email messages, online intake, and text chats.
¶ Persons who self-identified as Hispanic or Latino ethnicity were categorized as Hispanic. Persons who identified as American Indian, Alaskan Native, Black, African American, Native Hawaiian, Other Pacific Islander, multiracial, or any other race were categorized as non-White, NH. The non-White, NH category most commonly included persons who identified as Asian or Black.